CSIMarket
 
Regencell Bioscience Holdings Limited  (NASDAQ: RGC)
Other Ticker:  
 
 
Price: $5.5100 $0.06 1.101%
Day's High: $5.5311 Week Perf: -6.45 %
Day's Low: $ 5.45 30 Day Perf: -24 %
Volume (M): 2 52 Wk High: $ 32.44
Volume (M$): $ 11 52 Wk Avg: $6.25
Open: $5.45 52 Wk Low: $3.03



 Market Capitalization (Millions $) 72
 Shares Outstanding (Millions) 13
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is a Hong Kong-based company that specializes in the research, development, and commercialization of innovative regenerative medicine products. The company was incorporated in 2013 and is privately held.

Regencell Bioscience Holdings Limited has a team of highly experienced scientists, researchers, and executives who are committed to developing breakthrough treatments for a range of conditions, such as cancer, cardiovascular disease, diabetes, and multiple sclerosis. The company's research efforts are centered around the use of stem cells and other cell-based therapies to regenerate damaged tissues and organs.

Regencell Bioscience Holdings Limited has developed several proprietary technologies, including a stem cell isolation and culture system that enables the production of large quantities of high-quality stem cells. The company also has a platform that allows for the identification of novel therapeutic targets and the development of drugs that can selectively target these targets.

Regencell Bioscience Holdings Limited's flagship product is its stem cell-based therapy for the treatment of osteoarthritis. This therapy involves the injection of autologous or allogeneic stem cells into the affected joint to stimulate the regeneration of cartilage and other tissues. The company has also developed cell-based therapies for the treatment of cardiovascular diseases, such as myocardial infarction and heart failure, as well as for the treatment of Alzheimer's disease.

Regencell Bioscience Holdings Limited has extensive collaborations with leading academic institutions and healthcare organizations to advance its research efforts. The company has also established partnerships with pharmaceutical companies for the development and commercialization of its products.

In addition to its research efforts, Regencell Bioscience Holdings Limited is committed to ensuring the safety and efficacy of its products through rigorous preclinical and clinical testing. The company adheres to the highest standards of regulatory compliance and operates in accordance with international guidelines for the development of regenerative medicine products.


   Company Address: 9/F Chinachem Leighton Plaza Causeway Bay 0
   Company Phone Number: 2155 0823   Stock Exchange / Ticker: NASDAQ RGC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stocks on the Move

Regencell Bioscience Holdings A Deep Dive into Company Performance and Market Influence

Published Wed, Aug 7 2024 7:13 PM UTC

Regencell Bioscience Holdings Limited has been making waves in the market recently, with its shares trailing the overall market performance. In the fourth quarter of 2023, the company managed to enhance its Leverage Ratio to a new low point of 0.05, thanks to the repayment of liabilities. This commendable achievement has positioned Regencell Bioscience Holdings at the forefr...

Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited Outshines Stock Market with Impressive Financial Turnaround in Q4 2023, Revealing a Promising Future Despite Deficit

The Legal Cannabis industry researchers have recently analyzed the fourth quarter results of Regencell Bioscience Holdings Limited (RGC), providing valuable insights and observations. In the period between April and June 2023, RGC reported an operating deficit of $-6.273671 million, as it has not generated any revenue during this quarter. However, this news should be viewed positively, considering that it represents an improvement compared to the same period the previous year, where the operating deficit was $-7.61777 million.
This progress in reducing the operating deficit has instilled confidence among countless analysts regarding Regencell Bioscience Holdings Limited. One significant observation is the mitigation of the deficit, as the diminishing returns have decreased from the same period a year before. This is a noteworthy development in the fourth quarter of the 2023 earnings season, with a loss of $-6.062 million, compared to $-7.595 million in the fourth quarter of 2022.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com